SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound to a fresh 52-week high and push through a key round-number level are driving attention, with traders cheering the momentum while others question whether the breakout can hold without a stronger catalyst. Earnings and pipeline progress are also in view, alongside the stocks appeal as a dividend-paying defensive holding.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Anticipation of Lillys quarterly results and analyst expectations for continued growth in its obesity-drug business are driving discussion. Traders are debating whether Foundayo and the broader GLP-1 pipeline can sustain Lillys lead against Novo and other competitors, with optimism about demand balanced by concerns over valuation and competition.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras investigational treatment for menopause-related hot flashes: traders are focused on clinical data presented at a menopause conference and the anticipated 12-week results, following encouraging Phase 2 findings. Optimism about the drugs efficacy and safety is tempered by debate over whether the presentation adds meaningfully new evidence, alongside frustration about volatility and selling pressure.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centruss steep selloff is largely being linked by traders to equity and warrant offerings, dilution concerns, and the cost and execution risks of expanding enrichment capacity, alongside weakness across nuclear stocks. Bulls point to DOE and HALEU contracts and the companys role in domestic nuclear fuel supply, while skeptics argue its valuation remains hard to justify and debate whether the decline has bottomed.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies expanded stock buyback program, raised to $100 million and extended into 2027, is drawing attention. Some traders see the repurchases as support for PURR, while others question their effect as the company focuses on accumulating HYPE and the token remains weak.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Brazils presidential runoff is the main focus, with traders positioning for a possible Petrobras rally if Flvio Bolsonaro wins and expecting a more shareholder-friendly policy direction; talk of partial privatization remains hypothetical. The bullish election trade is accompanied by caution about a potential sell-the-news reaction and uncertainty over the outcome.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

Renewed selling in Chinese internet stocks has erased a short-lived China-tech rally, leaving KWEB near multi-year lows. Traders are divided between buying the oversold pullback and expecting a rebound, and arguing that weak demand, limited market support and persistent policy and geopolitical risks keep the sector under pressure.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRAIMFINZI combination drew attention after Phase 3 results showed a substantial survival benefit in first-line extensive-stage small-cell lung cancer. Traders see the data as a potential growth driver and a boost to Amgens oncology pipeline, while debating how much it could add to the business.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as crude prices climb amid Middle East supply concerns and reports of attacks affecting shipping, while the Russian diesel supply deal has added to debate over whether new supply could ease fuel prices. Traders are split between bullish momentum and expectations of a sharp pullback, with some questioning deal headlines and warning that the leveraged ETF can swing sharply.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastems encouraging early VS-7375 results in KRAS G12D cancers, including pancreatic cancer, are driving attention, along with FDA alignment on a planned Phase 3 study. Traders are optimistic about the drugs potential but debate whether small early cohorts will hold up in larger trials and weigh the clinical progress against dilution from the share offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomerica, Inc. Q2 Loss Widens

(RTTNews) - Biomerica, Inc. (BMRA) announced earnings for its second quarter that Increased from the same period last year...

Biomerica Stock Slumps After Reverse Stock Split Announcement: Retail’s Disappointed

Equity

Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock on Monday.

Biomerica Adds Most New Retail Followers Among Biotechs After UAE Nod For Prostate Cancer Screening Test

The latest approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

Biomerica Inc.

Bullish Sentiment

Shares of Biomerica, Inc. (BMRA) traded nearly 26% lower on Wednesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biomerica.com/news/news-details/2025/Biomerica-Announces-Reverse-Stock-Split/default.aspx">said</a> it would implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock to increase its bid price.The stock split will be effective at 12:01 a.m. ET on April 21, and Biomerica’s common stock will begin trading on a split-adjusted basis when the market opens on Monday, the company said.Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock, subsequently reducing the number of outstanding shares from about 20.4 million to about 2.5 million.The move is aimed at enabling the biomedical technology company to regain compliance with the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market.To regain compliance, Biomerica’s common stock must close at or above a $1.00 per share bid price for at least ten consecutive business days prior to May 5.On Stocktwits, retail sentiment around Biomerica fell from ‘extremely bullish’ to ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’.<figure class="image"><img style="aspect-ratio:1306/306;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_1_33_21_PM_png_82a4f25b9a.webp" alt="BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1306" height="306"><figcaption>BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that today marks a good opportunity to buy the stock as the reverse split is “not that big of a deal” and the company has a strong cash runway.<stembedurl>https://stocktwits.com/ildamiano1/message/611809693</stembedurl>Biomerica’s cash and cash equivalents totaled $3.06 million as of February-end, marking an increase from $2.37 million at the end of the second quarter (Q2) of fiscal 2025.<a href="https://stocktwits.com/symbol/BMRA">BMRA stock</a> is up by about 42% year-to-date but has fallen 43% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-made-900-million-dollars-from-china-business-in-2024-report/chQPqv2RbOH">Ford Made $900M From China Business In 2024, Says Report: Retail Sentiment Brightens But Still Bearish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Vanguard Extended Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.68
Prev Close	$1.68
Open	$1.68
Dividend Yield	0.00%
50-Day Moving Average	$2.05
Beta	1.09
Avg. Volume	36,231.66
PE Ratio	-1.03

52-Week High	$3.09
52-Week Low	$1.45
Market Capitalization	$7.73M
EPS (Annual)	-$1.30
Price to Book	2.12
Revenue Per Employee	$89,060.00

Feed

News

Sentiment

Fundamentals

Info

BMRA Fundamentals